

Trobix Bio Presents In Vitro Data Validating TBX201 for Treatment of Diarrhea at Microbiome Connect Conference

Netanya, Israel, July 17, 2023 - Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced today the presentation of data showing *in vitro* validation of its orally administered precision medicine TBX201 to alleviate diarrhea induced by Irinotecan chemotherapy. The data was presented at the Microbiome Connect conference, held in Amsterdam on July 5-6, 2023.

Treatment with Irinotecan, a first-line chemotherapy drug used to treat about 100,000 cancer patients annually, causes severe and sometimes life-threatening diarrhea that can disrupt cancer treatment. Irinotecan is metabolized in the human gut to its toxic form SN38 by the microbiome bacteria β -glucuronidase enzyme (GUS), causing the diarrhea.

TBX201 works by turning off the production of GUS by the microbiome *E.coli* that normally produce it. Trobix Bio converges engineered phage, CRISPR-Cas3 and synthetic biology to develop TBX201 and other orally available therapeutic candidates. TBX201 consists of modified phage carrying a specific DNA cargo, designed to inhibit the bacterial GUS enzyme, in several *E.coli* strains in order to prevent formation of the toxic SN38 metabolite of irinotecan.

The new *in vitro* data presented at Microbiome Connect conference showed dose-dependent and statistically significant reduction in production of SN38 in the targeted *E.coli* strain treated with TBX201 and irinotecan. Moreover, thanks to CRISPR technology incorporated into TBX201, it also successfully converted the targeted bacterial population, to enrich it with GUS-inhibited bacteria over time. The data provide *in vitro* proof of concept for TBX201, and further validate the company's TBX™ technology platform. Click [here](#) for the full poster presentation.

Dr. Adi Elkeles, CEO of Trobix Bio, said: "These *in vitro* data are an important validation, demonstrating the potential of TBX201 and our proprietary TBX™ technology platform. It means that TBX201 has the potential to make a clinically meaningful difference for cancer patients by alleviating diarrhea caused by irinotecan. We believe it could allow physicians to complete more irinotecan treatment protocols, potentially saving lives, while also reducing the need for medical intervention and improving these patients' quality of life. We are now working on preclinical proof of concept studies with TBX201 and look forward to initiating IND enabling studies next year."

Trobix also is initiating preclinical proof of concept studies of TBX301, which utilizes target microbiome bacteria to produce and deliver IL-10 locally in the gut to treat colitis caused by immune checkpoint inhibitor therapeutics (ICI). ICI causes severe life-threatening colitis, necessitating interruption of the cancer treatment.



Trobix Bio (www.trobix.bio) is an Israeli biotech company pioneering the field of human microbiome via its TBX™ platform technology to develop orally administered therapeutics to reduce life-threatening side effects associated with leading oncology therapeutics. The company's products may enable physicians to complete more oncology treatments at optimal doses while improving cancer patients' quality of life.

For further information please contact:

Trobix Bio

Dr. Adi Elkeles
Chief Executive Officer
Tel: +972-54-6402333
adie@trobixbio.com

Investors & media

Chris Maggos
Cohesion Bureau
+41 79 367 6254
chris.maggos@cohesionbureau.com

